ATC code None Synonyms BC 3781 PubChem CID 25185057 | Legal status Investigational CAS Number 1061337-51-6 ChemSpider 32701544 | |
 | ||
Lefamulin is a pleuromutilin antibiotic that is being developed by Nabriva Therapeutics for the treatment of acute bacterial skin and skin-structure infections (ABSSSI). It was granted fast track status by the US Food and Drug Administration in 2014. As of May 2016, it is in phase III clinical trials.
Spectrum of activity
Lefamulin has in vitro activity against Streptococcus viridans, Moraxella catarrhalis, Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA), among other bacteria.
References
Lefamulin Wikipedia(Text) CC BY-SA